Paramyxovirus activation and inhibition of innate immune responses.
Paramyxoviruses represent a remarkably diverse family of enveloped nonsegmented negative-strand RNA viruses, some of which are the most ubiquitous disease-causing viruses of humans and animals. This review focuses on paramyxovirus activation of innate immune pathways, the mechanisms by which these RNA viruses counteract these pathways, and the innate response to paramyxovirus infection of dendritic cells (DC). Paramyxoviruses are potent activators of extracellular complement pathways, a first line of defense that viruses must face during natural infections. We discuss mechanisms by which these viruses activate and combat complement to delay neutralization. Once cells are infected, virus replication drives type I interferon (IFN) synthesis that has the potential to induce a large number of antiviral genes. Here we describe four approaches by which paramyxoviruses limit IFN induction: by limiting synthesis of IFN-inducing aberrant viral RNAs, through targeted inhibition of RNA sensors, by providing viral decoy substrates for cellular kinase complexes, and through direct blocking of the IFN promoter. In addition, paramyxoviruses have evolved diverse mechanisms to disrupt IFN signaling pathways. We describe three general mechanisms, including targeted proteolysis of signaling factors, sequestering cellular factors, and upregulation of cellular inhibitors. DC are exceptional cells with the capacity to generate adaptive immunity through the coupling of innate immune signals and T cell activation. We discuss the importance of innate responses in DC following paramyxovirus infection and their consequences for the ability to mount and maintain antiviral T cells.
Department of Microbiology and Immunology, Wake Forest School of Medicine, Winston-Salem, NC 27157-1064, USA. Electronic address: gparks@wakehealth.edu.
Griffith D
GD
Parks
Martha A
MA
Alexander-Miller
D000818:Animals; D003167:Complement Activation; D003169:Complement Inactivator Proteins / Q000276:immunology; D003713:Dendritic Cells / Q000276:immunology / Q000821:virology; D016679:Genome, Viral / Q000235:genetics; D054884:Host-Pathogen Interactions / Q000276:immunology*; D006801:Humans; D007113:Immunity, Innate / Q000276:immunology*; D007370:Interferon Type I / Q000378:metabolism*; D008213:Lymphocyte Activation; D008958:Models, Molecular; D010252:Paramyxoviridae / Q000235:genetics / Q000276:immunology* / Q000502:physiology; D018184:Paramyxoviridae Infections / Q000276:immunology* / Q000821:virology; D012367:RNA, Viral / Q000235:genetics / Q000276:immunology; D015398:Signal Transduction / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology / Q000821:virology; D014764:Viral Proteins / Q000235:genetics / Q000276:immunology; D014775:Virus Activation; D014779:Virus Replication
D003169:Complement Inactivator Proteins; D007370:Interferon Type I; D012367:RNA, Viral; D014764:Viral Proteins
DC; ISG; ORF; WT; dendritic cells; innate immunity; interferon; interferon-stimulated gene; moDC; monocyte-derived DC; open reading frame; pDC; paramyxovirus; plasmacytoid DC; wild type